A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration.

ABSTRACT: Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody-based regimens have demonstrated potency regarding virus neutralization and HBsAg clearance. However, high dosages or frequent dosing are required for virologic control. In this study, a dual-domain-engineered anti-hepatitis B virus (HBV) therapeutic antibody 73-DY is developed that exhibits significantly improved efficacy regarding both serum and intrahepatic viral clearance. In HBV-tolerant mice, administration of a single dose of 73-DY at 2 mg kg^-1 is sufficient to reduce serum HBsAg by over 3 log₁₀ IU mL^-1 and suppress HBsAg to < 100 IU mL^-1 for two weeks, dem

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC11022716 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature